Deals
The pact between Madrigal Pharmaceuticals and Ruzhou Ribo Life Sciences could complement the former’s Rezdiffra, the first FDA-approved therapy for MASH. That drug made $287.3 million in the third quarter of 2025.
FEATURED STORIES
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Speaking on the sidelines of the J.P. Morgan Healthcare Conference, Novo business development executive Tamara Darsow said the company is gunning for obesity and diabetes assets.
Buying vaccine biotech Dynavax was an easy choice for Sanofi despite anti-vaccine moves by the Trump administration.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Cerevel Therapeutics, which spun out of Pfizer two years ago, entered into a business combination deal with Arya Sciences Acquisition Corp II, a special purpose acquisition company (SPAC) sponsored by Perceptive Advisors.
COVID-19 put many businesses on hold, but not biotech. This sector is growing at record speeds, and only a small portion of the capital deals are related to the pandemic.
Rumors are flying that Paris-based Sanofi has a $50 billion budget for mergers and acquisitions and is taking a look at U.S.-based biotech companies. At the top of the list, reportedly, is South San Francisco-based Principia Biopharma.
Unum Therapeutics announced on Monday that it has successfully completed its acquisition of Kiq LLC, a privately held biotechnology company with a focus on the discovery and development of precision kinase inhibitors.
Specifically, the report indicated that biotechnology companies drove the healthcare industry to make up almost two-thirds of IPO activity in the second quarter of 2020.
Relay Therapeutics was the No. 3 company in BioSpace’s NextGen Bio Class of 2018, Top 20 Life Science Startups to Watch in 2018.
Today, Gilead announced that it was acquiring a 49.9% equity interest in Pionyr Immunotherapeutics for $275 million and exclusive option to buy the rest of the company.
The company is focused on developing cell and gene therapies based on a proprietary DNA modification, gene editing and delivery technology.
BioSpace takes a look at some of the most recent IPO plans from companies across the globe.
Under terms of the deal, Novo Nordisk paid $725 million upfront to Sofinnova for the Waltham, Mass.-based Corvidia, a company focused on the development of transformational therapies for cardio-renal diseases.